MedTrace Logo

Impact of PharmaCloud on Pharmacist-Led Medication Reconciliation Efficiency and Error Detection Among Taiwanese Inpatients

NCT07727278 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2026-07-27

No results posted yet for this study

Summary

Taiwan's National Health Insurance Administration PharmaCloud provides cross-institutional medication access to reimbursed medication records to support best possible medication history (BPMH) compilation. However, its utility among internal medicine inpatients, who typically present with complex regimens and frequent medication changes, remains understudied. This study aims to evaluate the impact of PharmaCloud integration on pharmacist-led medication reconciliation (MedRec) efficiency and error detection among internal medicine inpatients at both admission and discharge.

The non-randomized, single-center study was conducted from May to November 2024 at the Far Eastern Memorial Hospital in Taiwan. Internal medicine inpatients taking at least one pre-admission chronic medication were enrolled and assigned to standard medication reconciliation protocol (control) or PharmaCloud-integrated medication reconciliation (experimental). Best possible medication history compilation time was recorded across two stages: preparation and interview. Medication discrepancies were identified at admission and discharge and classified as intentional or unintentional.

Conditions

  • Medication Reconciliation
  • Best Possible Medication History
  • Medication Discrepancy

Interventions

OTHER

PharmaCloud-integrated medication reconciliation

The intervention entailed supplementing in-house electronic medical record with data from PharmaCloud, a platform launched by Taiwan's National Health Insurance Administration to enable cross-institutional access to reimbursed medication records.

Sponsors & Collaborators

  • National Yang Ming Chiao Tung University

    collaborator OTHER

  • Far Eastern Memorial Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07727278 on ClinicalTrials.gov